Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
John Todd joined Singulex in 2007 and has championed Singulex’s clinical programs to demonstrate the clinical utility of SMC™ for cardiovascular disease risk prediction and patient management. John has substantial diagnostics development experience, having developed products to address unmet clinical needs in numerous disease areas and successfully establishing their medical advantage.
Prior to joining Singulex, John held leadership and executive positions at numerous healthcare companies including Chiron Diagnostics, Bayer Diagnostics, Baxter Healthcare, NUGEN Technologies, Protogene Labs and ENZO Biochem. He has co-authored over 60 peer-reviewed publications and 90 scientific abstracts, been issued 15 patents and presented at over 100 biomedical scientific conferences. John has received 6 SBIR grants for the development and commercialization of diagnostic products.
John received a Ph.D. in Biochemistry and a B.S. in Biology from the University of Southern California, followed by post graduate training in Cell and Molecular Biology at the Sabatini Lab, New York University Medical Center.
Bob Brousseau joined Singulex in 2015. He has 20 years of commercial leadership experience that includes sales, marketing, operations, and reimbursement. Most recently he was with Agendia as Executive Vice President of Global Sales. Prior to Agendia, he had leadership roles with Genoptix, Cypress Bioscience, Verus Pharmaceuticals, and Elan Pharmaceuticals. Bob has a rich history with cancer diagnostics and has been responsible for building several start-up commercial organizations.
Bob earned a B.A. in Finance from the University of Oklahoma and an M.B.A. from Southern Methodist University.
Brandon has served as Vice President of Finance since 2016. Since joining Singulex in 2012 as Director of Financial Planning & Analysis, Brandon has accepted roles of increasing responsibility including oversight of Medical Billing, IT, Supply Chain, Legal and Facilities. Prior to Singulex, Brandon spent three years in a finance capacity at Novartis Vaccines & Diagnostics. Prior to that, Brandon spent ten years at Genentech working in the areas of Finance, Accounting, Treasury & Supply Chain.
Brandon received a B.S. degree in Cell & Developmental Biology from the University of California at Santa Barbara. He also earned an M.B.A. with Finance emphasis from the University of San Francisco.
Jeff Bishop joined Singulex in 2013. Jeff has worked in the diagnostics industry for more than 13 years at Biosite, Inverness Medical Innovations and Alere. During this time, Jeff held various scientific and leadership positions within the R&D organization including Vice President of R&D for Point of Care platforms and Vice President of R&D for Drugs of Abuse platforms. Jeff has extensive experience working with biomarkers and has led the development of many drug and biomarker assays on numerous platforms across a wide range of disease states.
Jeff earned both an M.S. and a Ph.D. in Bioengineering from the University of California, San Diego and holds a B.S. in Chemical Engineering from Brigham Young University. He also holds an RAC certification in Regulatory Affairs.
Jessica McCarthy joined Singulex in 2016, responsible for the company’s brand, worldwide product and service launches and all advertising and promotion. She brings more than 20 years of experience building effective marketing teams and executing successful, high-growth marketing strategies. Prior to Singulex, Jessica held leadership roles of increasing responsibility at Blue Shield of California, and was most recently Vice President of Integrated Marketing and Customer Experience. Before that, she was a marketing lead at Silicon Valley Bank and managed Fortune 500 and start-up accounts at several global advertising agencies.
Jessica earned a BA in Religion and Art History from Syracuse University and completed the Women’s Senior Leadership Program at Northwestern University’s Kellogg School of Management. In 2014, The San Francisco Business times named her one of the “Most Influential Women in the Bay Area,” and inducted her into the “Most Influential Women in the Bay Area Hall of Fame” in 2015.
Mark Stene has over 25 years of experience managing and growing clinical laboratories and operations. Prior to joining Singulex, Mark held a number of key leadership roles at Quest Diagnostics, including Operations Director for the reference laboratories of both the Nichols Institute and Focus Diagnostics and Director of Laboratory Operations for the Southern California Business Unit. Mark also held roles of increasing responsibility in R&D, operations and general management at Endocrine Sciences and the successor companies of Esoterix and LabCorp.
Mark earned a Ph.D. in Experimental Pathology, an M.B.A. and a B.S. in Biochemistry from the University of California, Los Angeles. He is licensed in California as a Clinical Laboratory Scientist (CLS) and holds a Certification of Qualification (COQ) for the State of New York.
Thomas Schlumpberger joined Singulex in 2015 with more than 16 years experience in the IVD, life science and pharmaceutical industry. Previously, Thomas held executive and leadership positions at Annai Systems, AliveCor, Invitae (f/k/a Locus Development), Epocal, Nektar and Affymetrix. Thomas had responsibility for commercialization and product launches at Invitae as Chief Commercial Officer and at Epocal as Sr VP of International Sales and Business Development. Before joining the healthcare industry, Thomas served as a consultant at McKinsey & Company.
Thomas earned a Ph.D. in Molecular & Cell Biology from the University of California, Berkeley and holds a M.S. in Electrical Engineering from the Technische Universitaet Muenchen.
Karen Richards joined Singulex in 2012. Karen has worked in the in vitro diagnostics industry for over 30 years. She has held executive and leadership positions in Regulatory Affairs, Quality Assurance and Clinical Affairs at Tethys, Celera, Novartis Vaccines & Diagnostics and Beckman Coulter. Karen has led numerous in vitro diagnostics clinical trial programs and regulatory submissions, enabling successful market entry of products into the U.S., Europe, Asia and Latin America. In addition, Karen has built many quality systems in compliance with ISO 9001, 13485, and U.S. Quality System Regulations.
Karen holds a B.A. in Biological Sciences from the University of California, Santa Cruz and an RAC certification in Regulatory Affairs.
Karen is currently employed by Precision for Medicine and is providing consulting services to Singulex.
Patricia Ryan joined Singulex in 2014, bringing over 20 years of experience focused on the internal control environment. Most recently, Patty served as the Latin American and Asia Pacific Regional Compliance Officer for Novartis Vaccines & Diagnostics as well as the U.S. Compliance Officer for the Diagnostics business, providing compliance support in all aspects of commercial activities. Patty joined Novartis Vaccines & Diagnostics as a Sarbanes- Oxley Compliance; Internal Controls Analyst. Patty also spent several years as a Corporate Internal Auditor for AT&T.
Patty has worked for over a decade in local Public Accounting Firms in the San Francisco Bay area leading auditing and consulting service engagements. Patty holds a B.S. in Business Administration with a concentration in Accounting from San Jose State University. She is a Certified Public Accountant and a Certified Internal Auditor.
Byron Clendenen joined Singulex in 2014 and possesses 25 years of HR leadership experience. Previously, Byron served and led HR functions in diverse settings such as CollabNet, Inc., within the enterprise cloud development software tools & services space; Vpacket Communications within the VoIP telecom space; Integrated Systems within the embedded software space; and Toshiba America MRI within the medical diagnostic imaging space.
Byron has contributed in privately and publicly held settings, and has developed, managed, and refined HR functions and programs for start-ups as well as for mature, multi-national organizations.
Byron earned a B.A. in Psychology from the University of California, Berkeley, and an M.A. in Psychology from San Francisco State University. He additionally possesses SPHR certification.
Advisory Board
Richard L. Popp, M.D., has served as Chairman of the Singulex Medical Advisory Board since 2012. Dr. Popp is a Professor of Medicine (Emeritus) at Stanford University School of Medicine, where he has served in numerous academic and administrative positions since joining the Stanford faculty in 1971. He received his medical degree from Johns Hopkins School of Medicine, where he performed his internship and residency before completing further clinical and research training in cardiology at Indiana University Medical Center and Stanford University Hospital.
During his career, Dr. Popp has focused his research on non-invasive methods for diagnosis and treatment of cardiovascular disease, pioneering the development of cardiac ultrasound technology and contributing to the continuous improvement of ultrasonic diagnostic methods. The author of over 270 publications, Dr. Popp is a former President of the American College of Cardiology, The American Society of Echocardiography and The Association of University Cardiologists, and served as Chairman of the American Board of Internal Medicine’s (ABIM) Cardiovascular Diseases Subspecialty Board. Dr. Popp’s continuing interest in the development of technologies that will enhance patient care and potential outcomes, combined with his substantial breadth of experience and achievement in cardiovascular medicine, provides an invaluable contribution to our Medical Advisory Board.